JGB1741

Research use only, not for human use.

JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.

JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.(In Vitro):JGB1741 (1-10000 nM) inhibits the cell proliferation of K562, HepG2 and MDA-MB 231 cell lines. JGB1741 (0.01-1 μM) induces apoptosis of MDA-MB 231 and shows a cell cycle arrest at G1 phase with more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM) increases the global acetylation of H3K9, acetylated p53K382 levels and p53 expression.

ILS-JGB-1741

Chromatin/Epigenetic

Sirtuin

Aurora B

——

——

1256375-38-8

440.6

C27H24N2O2S

>98% (HPLC)

——

C(NCC1=CC=CC=C1)(=O)C=2C3=C(SC2/N=C/C=4C5=C(C=CC4O)C=CC=C5)CCCC3

——

(-20℃)

With Ice Pack

≥ 2 years